Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696

Kedudukan dalam Saham #3772
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Harga Saham
$5.34
Modal Pasaran
$4.43B
Perubahan (1 hari)
3.07%
Perubahan (1 tahun)
-39.48%
Negara
TW
Perdagangan Lin BioScience, Inc. (6696)

Kategori

Healthcare
Sejarah pecahan saham untuk Lin BioScience, Inc. (6696)
Saham Lin BioScience, Inc. (simbol: 6696) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham 6696 yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham 6696.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
Tidak cukup data untuk tarikh yang disediakan.
Pecahan saham untuk syarikat pesaing atau serupa
Syarikat Bilangan pecahan saham Gandaan Kumulatif Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH